StockNews.com Initiates Coverage on Can-Fite BioPharma (NYSE:CANF)

Equities research analysts at StockNews.com began coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a research note issued to investors on Thursday. The brokerage set a “sell” rating on the stock.

A number of other equities analysts also recently issued reports on CANF. HC Wainwright reiterated a “buy” rating and set a $18.00 price target on shares of Can-Fite BioPharma in a research report on Tuesday, November 12th. D. Boral Capital reissued a “buy” rating and set a $10.00 price objective on shares of Can-Fite BioPharma in a research note on Tuesday, February 18th.

Can-Fite BioPharma Price Performance

Shares of CANF opened at $1.76 on Thursday. Can-Fite BioPharma has a 1-year low of $1.29 and a 1-year high of $4.69. The firm has a market capitalization of $6.23 million, a PE ratio of -0.98 and a beta of 1.33. The company’s fifty day moving average price is $1.57 and its 200-day moving average price is $1.95.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Can-Fite BioPharma stock. BNP Paribas Financial Markets purchased a new stake in Can-Fite BioPharma Ltd. (NYSE:CANF) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 25,185 shares of the company’s stock, valued at approximately $41,000. BNP Paribas Financial Markets owned 0.71% of Can-Fite BioPharma at the end of the most recent reporting period. Hedge funds and other institutional investors own 21.00% of the company’s stock.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.